Researchers at the University of Washington have discovered that a drug currently approved by the FDA could help boost the efficacy of immunotherapy against a rare type of liver cancer that has previously been unresponsive to checkpoint inhibitors. The study focused on fibrolamellar carcinoma, a rare form of liver cancer that primarily affects adolescents and young adults. Unlike more common liver cancers, fibrolamellar carcinoma often does not respond to standard immunotherapy treatments, leaving patients with limited options.
The findings suggest that this FDA-approved drug may alter the tumor microenvironment, making it more susceptible to immune attack. By combining the drug with checkpoint inhibitors, researchers observed enhanced immune activity against cancer cells in preclinical models. This approach could potentially turn a cancer that was once resistant into one that responds to immunotherapy, offering new hope for patients.
While this study specifically targeted fibrolamellar carcinoma, the implications extend to other cancer types as well. The broader field of immunotherapy continues to attract significant research attention, with companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) exploring novel approaches to enhance treatment efficacy. Checkpoint inhibition therapy has revolutionized cancer treatment, but many tumors remain resistant, driving the need for combination strategies.
The University of Washington team plans to move forward with clinical trials to validate these findings in human patients. If successful, this repurposed drug could become a standard addition to immunotherapy regimens for fibrolamellar carcinoma and potentially other hard-to-treat cancers.
For more information, visit BioMedWire.
